An international, observational study based on secondary data describing the management and treatment of dapagliflozin in routine practice in patients with chronic kidney disease in central and eastern Europe.
Ladies and Gentlemen,
We invite you to participate in a multicenter observational study entitled:
An international, observational study based on secondary data describing the management and treatment of dapagliflozin in routine practice in patients with chronic kidney disease in central and eastern Europe. (OPTIMISECKD CEE)",
whose primary goal is to characterize the use of dapagliflozin in clinical practice by describing previously untreated patients who are treated with dapagliflozin for CKD.
In order to start the study, it is necessary to conclude an online contract, so please register and follow the information appearing on the computer screen.
Please fill out the form
registration and participation in the study.
Poland sp. z o.o.
ul. Postępu 14, 02-676 Warszawa
tel. +48 (22) 2457300
fax +48 (22) 4853007